Novartis Secures First FDA Approval of Oral BTK Inhibitor for Chronic Hives

By /

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment.

Scroll to Top